Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Elmer who wrote (5344)	9/18/1998 11:29:00 PM
From: Izzy	Read Replies (3) \| Respond to of 6136

David, thank you. I've owned VRTX in the past (lost money) and I'm hesistant to jump in again. But something obviously is going on to give the stock price a push (presumably the status of the PI clinical trials). It appears to me that the only reasonable PI to prescribe, at this time, is Viracept (? 2 billion+ dollar market; what? 200,000+ patients) as I cannot see any medical justification to prescribing Crixivan, Norvir, or any other PI. And, based on the earlier posts today, I don't even think I'm even interested in trying Sustiva (terrible drug side-effect profile; how did DD get a 3 mos "fast-tract" FDA approval?). However, I would like to try a regimen that includes Remune (if the clinical trial reports are very good, as suspected, this drug should go "fast-tract" FDA approval, IMO). So, I'm staying long on AGPH and IMNR. PS: Wonder how long it will take for Crix to disappear from the market scene. I don't think that Norvir is going anywhere. Dr. Oliver, what do you think?